var title_f0_19_304="Aortic dissection transesophageal echocardiogram";
var content_f0_19_304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/69234/aordis3t_conv.mp4?title=Aortic+dissection+transesophageal+echocardiogram\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic dissection transesophageal echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transesophageal echocardiogram shows large intimal tear of the ascending aorta with an intimal flap separating the false and true lumens. Spontaneous echo contrast is seen in the false lumen, a result of stasis of blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_304=[""].join("\n");
var outline_f0_19_304=null;
var title_f0_19_305="Botfly larva";
var content_f0_19_305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62332&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatobia hominis larva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An extracted Dermatobia hominis larva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter Lio, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_305=[""].join("\n");
var outline_f0_19_305=null;
var title_f0_19_306="Dry powder inhalers PI";
var content_f0_19_306=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Dry powder inhalers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 413px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These are pictures of different dry powder inhalers. The inhalers shown are: (A) Aerolizer, (B) HandiHaler, (C) Flexhaler, (D) Diskus, and (E) Twisthaler. There are 2 main types of dry powder inhalers, called single-dose inhalers and multiple-dose inhalers. The Aerolizer and HandiHaler are single-dose inhalers. The others in the picture are multiple-dose inhalers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dean Hess, RRT, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_306=[""].join("\n");
var outline_f0_19_306=null;
var title_f0_19_307="Sponge based negative pressure wound system";
var content_f0_19_307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sponge based negative pressure wound system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_307=[""].join("\n");
var outline_f0_19_307=null;
var title_f0_19_308="Zileuton: Pediatric drug information";
var content_f0_19_308=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Zileuton: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"    see \"Zileuton: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/1/14357?source=see_link\">",
"    see \"Zileuton: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zyflo CR&reg;;",
"     </li>",
"     <li>",
"      Zyflo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1042957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       5-Lipoxygenase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1042988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"      see \"Zileuton: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Children, Adolescents &ge;12 years, and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: 600 mg 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: 1200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Adjustment not necessary in renal dysfunction or with hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Contraindicated with hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zyflo&reg;: 600 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zyflo CR&reg;: 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1042994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extended release: Do not crush, cut, or chew tablet; administer within 1 hour after morning and evening meals.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3462557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1042958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For prophylaxis and chronic treatment of asthma (FDA approved in ages &ge;12 years and adults);",
"     <b>",
"      NOT",
"     </b>",
"     indicated for the relief of acute bronchospasm; therapy may continue during asthma exacerbations",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F235378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fever, headache, insomnia, malaise, nervousness, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased, hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, hypertonia, myalgia, neck pain/rigidity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngolaryngeal pain, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions, lymphadenopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Behavior/mood changes, hepatitis, hyperbilirubinemia, jaundice, liver failure, suicidality, suicide",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1042963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to zileuton or any component, active liver disease, or transaminase elevations &ge;3 times ULN",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13243830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in females &gt;65 years of age, patients with history of liver disease, and/or in those patients who consume substantial quantities of ethanol. Postmarketing reports of behavioral changes (eg, agitation, aggression, depression, insomnia, tremor) and sleep disorders have been noted; patients should be monitored accordingly and instructed to notify prescriber if neuropsychiatric changes occur.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1042964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Zileuton is not appropriate or indicated for the reversal of bronchospasm in acute asthma attacks, including status asthmaticus; therapy may be continued during acute asthma exacerbations. Increased serum transaminase levels and bilirubin have been reported (incidence: 3.2%); females &gt;65 years of age and patients with pre-existing elevated transaminases may be at greater risk. Serum ALT test is the most sensitive indicator of zileuton-associated liver injury; hepatic changes may resolve with continued treatment (usually within 3 weeks), remain unchanged, or progress to clinically significant injury. Monitor hepatic function at initiation and monthly during first 3 months of therapy, then every 2-3 months for the remainder of first year of therapy, and then periodically thereafter. Discontinue therapy and follow transaminases until normal if signs or symptoms of hepatic dysfunction present (eg, right upper quadrant pain, nausea, fatigue, lethargy, pruritus, jaundice, or &ldquo;flu-like&rdquo; symptoms) or serum transaminases &ge;5 times ULN. Zileuton increases serum theophylline concentrations (approximately doubled); consider theophylline dosage adjustment and monitor levels closely. Concomitant administration with warfarin may result in increased prothrombin times; monitor prothrombin times and adjust warfarin dose accordingly. Concomitant administration with propranolol may result in increased  propranolol AUC (approximately doubled); monitor patients closely, propranolol dosage adjustment may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F235367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Zileuton may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propranolol: Zileuton may increase the serum concentration of Propranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline: Zileuton may increase the serum concentration of Theophylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Zileuton may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1042977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Under fed conditions, the AUC of Zyflo CR&reg; is increased by 34% to 43%; recommend taking with food",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies. If a leukotriene modifier is needed during pregnancy, other agents are preferred (ACOG, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1042996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatic transaminases (prior to initiation and during therapy), specifically monitor serum ALT (prior to initiation, once a month for the first 3 months, every 2-3 months for the remainder of the first year, and periodically thereafter for patients receiving long-term therapy). Monitor vital signs and lung sounds prior to and periodically during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1042978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific 5-lipoxygenase inhibitor which inhibits leukotriene formation. Leukotrienes augment neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction (which contribute to inflammation, edema, mucous secretion, and bronchoconstriction in the airway of the asthmatic).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1042980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well-absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 1.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93%, primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and gastrointestinal; zileuton and N-dehydroxylated metabolite can be metabolized by CYP1A2, 2C9, and 3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Immediate release: 1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (~95% primarily as metabolites); feces (~2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: &lt;0.5% removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1043000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/1/14357?source=see_link\">",
"      see \"Zileuton: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zileuton is indicated for the chronic treatment of asthma. Take regularly as prescribed, even during symptom-free periods. Zileuton is not a bronchodilator; do not use to treat acute episodes of asthma. When taking zileuton, do not decrease the dose or stop taking any other antiasthma medications unless instructed by a physician. While using zileuton, seek medical attention if short-acting bronchodilators are needed more often than usual or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for a 24-period are needed. The most serious side effect of zileuton is elevation of liver enzyme tests. While taking zileuton, liver enzyme tests must be monitored on a regular basis. Contact prescriber immediately if you experience signs or symptoms of liver dysfunction (right upper quadrant pain, nausea, fatigue, lethargy, pruritus, jaundice, or &ldquo;flu-like&rdquo; symptoms). Notify prescriber if you experience any changes in sleep or mood. Zileuton can interact with other drugs. While taking zileuton, consult a physician before starting or stopping any prescription or nonprescription medicines.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16775 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_308=[""].join("\n");
var outline_f0_19_308=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235353\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042957\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042988\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235333\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235319\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042994\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3462557\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042958\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235378\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042963\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243830\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042964\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235367\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235328\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042977\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235329\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235341\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042996\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042978\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1042980\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043000\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16775\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16775|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=related_link\">",
"      Zileuton: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/1/14357?source=related_link\">",
"      Zileuton: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_19_309="Cross section intact tube";
var content_f0_19_309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 505px\">",
"   <div class=\"ttl\">",
"    Cross-section of intact fallopian tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 485px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic cross-section of fallopian tube demonstrating an intact serosa with a coagulated muscularis layer. The endosalpinx remains visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_309=[""].join("\n");
var outline_f0_19_309=null;
var title_f0_19_310="Variation small saphenous vein anatomy";
var content_f0_19_310=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Variation small saphenous vein anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 545px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Based on information from Schweighofer G, M&uuml;hlberger D, Brenner E. The anatomy of the small saphenous vein; fascial and neural relations, saphenofemoral junction, and valves. J Vasc Surg 2010; 51;982.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_310=[""].join("\n");
var outline_f0_19_310=null;
var title_f0_19_311="Ethinyl estradiol and norethindrone: Patient drug information";
var content_f0_19_311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ethinyl estradiol and norethindrone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/43/32442?source=see_link\">",
"     see \"Ethinyl estradiol and norethindrone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F168468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alyacen 1/35;",
"     </li>",
"     <li>",
"      Alyacen 7/7/7;",
"     </li>",
"     <li>",
"      Aranelle&reg;;",
"     </li>",
"     <li>",
"      Balziva&trade;;",
"     </li>",
"     <li>",
"      Brevicon&reg;;",
"     </li>",
"     <li>",
"      Briellyn;",
"     </li>",
"     <li>",
"      Cyclafem&trade; 1/35;",
"     </li>",
"     <li>",
"      Cyclafem&trade; 7/7/7;",
"     </li>",
"     <li>",
"      Dasetta&trade; 1/35;",
"     </li>",
"     <li>",
"      Dasetta&trade; 7/7/7;",
"     </li>",
"     <li>",
"      Estrostep&reg; Fe;",
"     </li>",
"     <li>",
"      Femcon&reg; Fe;",
"     </li>",
"     <li>",
"      femhrt&reg;;",
"     </li>",
"     <li>",
"      femhrt&reg; Lo;",
"     </li>",
"     <li>",
"      Generess&trade; Fe;",
"     </li>",
"     <li>",
"      Gildess&reg; FE 1.5/30;",
"     </li>",
"     <li>",
"      Gildess&reg; FE 1/20;",
"     </li>",
"     <li>",
"      Jevantique&trade; [DSC];",
"     </li>",
"     <li>",
"      Jinteli&trade;;",
"     </li>",
"     <li>",
"      Junel&reg; 1.5/30;",
"     </li>",
"     <li>",
"      Junel&reg; 1/20;",
"     </li>",
"     <li>",
"      Junel&reg; Fe 1.5/30;",
"     </li>",
"     <li>",
"      Junel&reg; Fe 1/20;",
"     </li>",
"     <li>",
"      Leena&reg;;",
"     </li>",
"     <li>",
"      Lo Loestrin&trade; Fe;",
"     </li>",
"     <li>",
"      Loestrin&reg; 21 1.5/30;",
"     </li>",
"     <li>",
"      Loestrin&reg; 21 1/20;",
"     </li>",
"     <li>",
"      Loestrin&reg; 24 Fe;",
"     </li>",
"     <li>",
"      Loestrin&reg; Fe 1.5/30;",
"     </li>",
"     <li>",
"      Loestrin&reg; Fe 1/20;",
"     </li>",
"     <li>",
"      Microgestin&reg; 1.5/30;",
"     </li>",
"     <li>",
"      Microgestin&reg; 1/20;",
"     </li>",
"     <li>",
"      Microgestin&reg; Fe 1.5/30;",
"     </li>",
"     <li>",
"      Microgestin&reg; Fe 1/20;",
"     </li>",
"     <li>",
"      Modicon&reg;;",
"     </li>",
"     <li>",
"      Necon&reg; 0.5/35;",
"     </li>",
"     <li>",
"      Necon&reg; 1/35;",
"     </li>",
"     <li>",
"      Necon&reg; 10/11;",
"     </li>",
"     <li>",
"      Necon&reg; 7/7/7;",
"     </li>",
"     <li>",
"      Norinyl&reg; 1+35;",
"     </li>",
"     <li>",
"      Nortrel&reg; 0.5/35;",
"     </li>",
"     <li>",
"      Nortrel&reg; 1/35;",
"     </li>",
"     <li>",
"      Nortrel&reg; 7/7/7;",
"     </li>",
"     <li>",
"      Ortho-Novum&reg; 1/35;",
"     </li>",
"     <li>",
"      Ortho-Novum&reg; 7/7/7;",
"     </li>",
"     <li>",
"      Ovcon&reg; 35;",
"     </li>",
"     <li>",
"      Ovcon&reg; 50 [DSC];",
"     </li>",
"     <li>",
"      Tilia&trade; Fe;",
"     </li>",
"     <li>",
"      Tri-Legest&trade; Fe;",
"     </li>",
"     <li>",
"      Tri-Norinyl&reg;;",
"     </li>",
"     <li>",
"      Wera&trade;;",
"     </li>",
"     <li>",
"      Wymzya&trade; Fe;",
"     </li>",
"     <li>",
"      Zenchent Fe&trade;;",
"     </li>",
"     <li>",
"      Zenchent&reg;;",
"     </li>",
"     <li>",
"      Zeosa&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F168469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Brevicon&reg; 0.5/35;",
"     </li>",
"     <li>",
"      Brevicon&reg; 1/35;",
"     </li>",
"     <li>",
"      FemHRT&reg;;",
"     </li>",
"     <li>",
"      Loestrin&trade; 1.5/30;",
"     </li>",
"     <li>",
"      Minestrin&trade; 1/20;",
"     </li>",
"     <li>",
"      Ortho&reg; 0.5/35;",
"     </li>",
"     <li>",
"      Ortho&reg; 1/35;",
"     </li>",
"     <li>",
"      Ortho&reg; 7/7/7;",
"     </li>",
"     <li>",
"      Select&trade; 1/35;",
"     </li>",
"     <li>",
"      Synphasic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for birth control, do not smoke. Cigarette smoking raises the chance of unsafe heart and blood-related side effects. This chance is higher with age (older than 35 years of age) and with heavy smoking (15 or more cigarettes per day). Birth control pills do not stop the spread of diseases caused by having sex.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691539",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to put off soft, brittle bones (osteoporosis) in women after change of life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691649",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or lower the signs of stopping periods (menopause).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat endometriosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691841",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat women with hypogonadism.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heavy bleeding during monthly periods (menstruation).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ethinyl estradiol, norethindrone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Blood clots, breast cancer, diseased arteries in the brain, disease of a heart valve with problems, endometrial cancer, heart disease, high blood pressure, liver disease, liver tumor, very bad headache, tumor where estrogen makes it grow, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703789",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have surgery and need bed rest.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701021",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a heavy smoker (more than 15 cigarettes per day) and older than 35 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not started your period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701347",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you do not have a uterus and are using this drug to treat signs of stopping periods (menopause) or to put off soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703881",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you turned yellow during pregnancy or with estrogen-based or hormone contraceptive use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug for pimples (acne), you need to be at least 15 years of age.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any blood flow problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698524",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), you will need to watch your blood sugar closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have migraine headaches, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698554",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do monthly breast self-exams and have a gynecologic exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort, dong quai, black cohosh, saw palmetto, red clover, or ginseng with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking. People older than 35 years of age and/or smoking more than 15 cigarettes per day have more chance for heart disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698231",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Period (menstrual) changes. These include lots of bleeding, spotting, or bleeding between cycles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gallbladder disease, blood clots, heart attacks, and other blood vessel problems may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in how contact lenses feel in the eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A lump in the breast or breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696101",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug works best when used with calcium/vitamin D and weight-bearing workouts like walking or PT (physical therapy).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698535",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you miss 2 periods in a row, take a pregnancy test before starting a new dosing cycle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Missed dosing facts may be found in the package insert or call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699251",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect Estrostep&reg; from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12451 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_311=[""].join("\n");
var outline_f0_19_311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168468\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F168469\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027212\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027214\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027213\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027218\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027219\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027221\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027216\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027217\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027222\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027223\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/43/32442?source=related_link\">",
"      Ethinyl estradiol and norethindrone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_19_312="Ceftriaxone: Pediatric drug information";
var content_f0_19_312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ceftriaxone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"    see \"Ceftriaxone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/39/24180?source=see_link\">",
"    see \"Ceftriaxone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rocephin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ceftriaxone for Injection;",
"     </li>",
"     <li>",
"      Ceftriaxone Sodium for Injection BP;",
"     </li>",
"     <li>",
"      Rocephin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Third Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M., I.V. (",
"     <b>",
"      Note:",
"     </b>",
"     Use cefotaxime in place of ceftriaxone if hyperbilirubinemia is present or patient is receiving calcium-containing intravenous solutions):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      General dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &lt;7 days: 50 mg/kg/day given every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &ge;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;2000 g: 50 mg/kg/day given every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 50-75 mg/kg/day given every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gonococcal infections",
"     </b>",
"     (CDC, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: 25-50 mg/kg as a single dose (maximum dose: 125 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 25-50 mg/kg/day (maximum dose: 125 mg) given every 24 hours for 7 days, up to 10-14 days if meningitis is documented",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmia neonatorum, treatment:",
"     </b>",
"     25-50 mg/kg as a single dose (maximum dose: 125 mg)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"      see \"Ceftriaxone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     I.M., I.V.: 50-75 mg/kg/day divided every 12-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Chancroid:",
"     </b>",
"     I.M.: 50 mg/kg as a single dose (maximum dose: 250 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Epiglottitis:",
"     </b>",
"     I.M., I.V.: 50-100 mg/kg once daily; reported duration of treatment ranged from 2-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Gonococcal infections",
"     </b>",
"     (CDC, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Epididymitis, acute: I.M.: 250 mg in a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Uncomplicated cervicitis, pharyngitis, proctitis, urethritis, vulvovaginitis; treatment and prophylaxis: I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;45 kg: 125 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;45 kg: 250 mg as a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Complicated: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &le;45 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Peritonitis, arthritis, or bacteremia: 50 mg/kg/day once daily for 7 days; maximum dose: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Conjunctivitis: 50 mg/kg (maximum dose: 1000 mg) in a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Meningitis or endocarditis: 50 mg/kg/day divided every 12 hours for 10-14 days (meningitis), for 28 days (endocarditis); maximum dose: 2000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;45 kg:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Bacteremia, arthritis: 50 mg/kg once daily for 7 days (maximum dose: 2000 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Disseminated infection: 1000 mg/day once daily for 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Meningitis: 1000-2000 mg/dose every 12 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Endocarditis: 1000-2000 mg/dose every 12 hours for 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Conjunctivitis: I.M.: 1000 mg in a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Lyme disease (persistent arthritis, meningitis, encephalitis):",
"     </b>",
"     I.M., I.V.: 75-100 mg/kg once daily (maximum dose: 2000 mg) for 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     I.M., I.V.: 100 mg/kg/day divided every 12-24 hours; loading dose of 100 mg/kg may be administered at the start of therapy; maximum dose: 4000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Meningococcal infection, chemoprophylaxis  for high-risk contacts (close exposure to patients with invasive meningococcal disease):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;15 years: I.M.: 125 mg in a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;15 years: I.M.: 250 mg in a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Otitis media:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute bacterial: I.M.: 50 mg/kg in a single dose (maximum dose: 1000 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Persistent or relapsing: I.M., I.V.: 50 mg/kg once daily for 3 days (maximum dose: 1000 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against sexually transmitted diseases following sexual assault:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;45 kg: I.M.: 125 mg in a single dose (in combination with a azithromycin and metronidazole) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;45 kg: I.M., I.V.: 250 mg in a single dose (in combination with a azithromycin and metronidazole) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Skin/skin structure infections:",
"     </b>",
"     I.M., I.V.: 50-75 mg/kg/day in 1-2 divided doses (maximum dose: 2000 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Typhoid fever:",
"     </b>",
"     I.V.: 75-80 mg/kg once daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Dosage range:",
"     </b>",
"     I.M., I.V.: Usual dose: 1-2 g every 12-24 hours, depending on the type and severity of infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Chancroid:",
"     </b>",
"     I.M.: 250 mg as single dose (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cholecystitis, mild to moderate:",
"     </b>",
"     I.M., I.V.: 1-2 g every 12-24 hours for 4-7 days (provided source controlled)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Endophthalmitis:",
"     </b>",
"     I.V.: 2 g once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Gonococcal infections (CDC, 2010):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Conjunctivitis, complicated: I.M., I.V.: 1 g in a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Disseminated: I.M., I.V.: 1 g once daily for 24-48 hours; may switch to cefixime (after improvement noted) to complete a total of 7 days of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endocarditis: I.M., I.V.: 1-2 g every 24 hours for at least 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Epididymitis, acute: I.M.: 250 mg in a single dose with doxycycline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Meningitis: I.M., I.V.: 1-2 g every 12 hours for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Proctitis: I.M.: 250 mg in a single dose with doxycycline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prostatitis: I.M.: 125-250 mg in a single dose with doxycycline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Uncomplicated cervicitis, pharyngitis, urethritis: I.M.: 250 mg in a single dose with doxycycline or azithromycin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Infective endocarditis:",
"     </b>",
"     I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Native valve: 2 g once daily for 2-4 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     If using 2-week regimen, concurrent gentamicin is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prosthetic valve: 2 g once daily for 6 weeks [with or without 2 weeks of gentamicin (dependent on penicillin MIC)];",
"     <b>",
"      Note:",
"     </b>",
"     For HACEK organisms, duration of therapy is 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Enterococcus faecalis (resistant to penicillin, aminoglycoside, and vancomycin), native or prosthetic valve: 2 g twice daily for &ge;8 weeks administered concurrently with ampicillin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prophylaxis: 1 g 30-60 minutes before procedure. Intramuscular injections should be avoided in patients who are receiving anticoagulant therapy. In these circumstances, orally administered regimens should be given whenever possible. Intravenously administered antibiotics should be used for patients who are unable to tolerate or absorb oral medications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     American Heart Association (AHA) guidelines now recommend prophylaxis only in patients undergoing invasive procedures and in whom underlying cardiac conditions may predispose to a higher risk of adverse outcomes should infection occur. As of April 2007, routine prophylaxis for GI/GU procedures is no longer recommended by the AHA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Intra-abdominal infection, complicated, community-acquired, mild to moderate (in combination with metronidazole):",
"     </b>",
"     I.M., I.V.: 1-2 g every 12-24 hours for 4-7 days (provided source controlled)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Lyme disease:",
"     </b>",
"     I.V.: 2 g once daily for 14-28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     I.V.: 2 g every 12 hours for 7-14 days (longer courses may be necessary for selected organisms)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Meningococcal infection, chemoprophylaxis  for high-risk contacts (close exposure to patients with invasive meningococcal disease):",
"     </b>",
"     I.M.: 250 mg in a single dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pelvic inflammatory disease:",
"     </b>",
"     I.M.: 250 mg in a single dose plus doxycycline (with or without metronidazole) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pneumonia, community-acquired:",
"     </b>",
"     I.V.: 1 g once daily, usually in combination with a macrolide; consider 2 g/day for patients at risk for more severe infection and/or resistant organisms (ICU status, age &gt;65 years, disseminated infection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis against sexually transmitted diseases following sexual assault:",
"     </b>",
"     I.M.: 250 mg as a single dose (in combination with azithromycin and metronidazole) (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Pyelonephritis (acute, uncomplicated):",
"     </b>",
"     Females: I.V.: 1-2 g once daily (Stamm, 1993). Many physicians administer a single parenteral dose before initiating oral therapy (Warren, 1999).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Surgical prophylaxis:",
"     </b>",
"     I.V.: 1 g 30 minutes to 2 hours before surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cholecystectomy: 1-2 g every 12-24 hours, discontinue within 24 hours unless infection outside gallbladder suspected",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Syphilis:",
"     </b>",
"     I.M., I.V.: 1 g once daily for 10-14 days;",
"     <b>",
"      Note:",
"     </b>",
"     Alternative treatment for early syphilis, optimal dose, and duration have not been defined (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment is generally necessary in renal impairment;",
"     <b>",
"      Note:",
"     </b>",
"     Concurrent renal and hepatic dysfunction: Maximum dose: &le;2 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No adjustment necessary unless there is concurrent renal dysfunction, then dose should be a maximum of 2 g/day.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F148175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 1 g (50 mL); 2 g (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 250 mg, 500 mg, 1 g, 2 g, 10 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rocephin&reg;: 500 mg, 1 g [contains sodium ~83 mg (3.6 mEq) per ceftriaxone 1 g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F148159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     IVP: Administer over 2-4 minutes at a maximum concentration of 40 mg/mL. Rapid IVP injection over 5 minutes of a 2 g dose resulted in tachycardia, restlessness, diaphoresis, and palpitations in an adult patient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. intermittent infusion: Administer over 10-30 minutes; final concentration for I.V. administration should not exceed 40 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M. injection: May be diluted with SWI or 1% lidocaine to a final concentration of 250 mg/mL or may be concentrated by using the manufacturer's recommended diluent volume of 1% lidocaine with a resultant concentration of 350 mg/mL; administer I.M. injections deep into a large muscle mass",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F148255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W with KCl 10 mEq, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS with KCl 20 mEq, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS, mannitol 5%, mannitol 10%, sodium bicarbonate 5%, bacteriostatic water, sterile water for injection.",
"     <b>",
"      Incompatible",
"     </b>",
"     with calcium-containing solutions (eg, LR, Hartmann&rsquo;s solution, parenteral nutrition solutions).",
"     <b>",
"      Variable stability (consult detailed reference)",
"     </b>",
"     in peritoneal dialysis solutions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Daptomycin, diltiazem, famotidine, methotrexate, sodium bicarbonate, theophylline, tigecycline.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, amsacrine, azithromycin, caspofungin, filgrastim, fluconazole, labetalol, pentamidine, vinorelbine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, allopurinol, amifostine, amiodarone, anakinra, anidulafungin, aztreonam, bivalirudin, cisatracurium, , dexmedetomidine, docetaxel, doxorubicin liposome, drotrecogin alfa, etoposide phosphate, fenoldopam, fludarabine, foscarnet, gallium nitrate, gemcitabine, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), linezolid, melphalan, meperidine, morphine, paclitaxel, pantoprazole, pemetrexed, propofol, remifentanil, sargramostim, tacrolimus, telavancin, teniposide, thiotepa, vancomycin, warfarin, zidovudine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, aminophylline, amiodarone, amphotericin B cholesteryl sulfate complex, amsacrine, anakinra, aninulafungin, azithromycin, aztreonam, bivalirudin, calcium chloride, calcium gluconate, caspofungin, cisatracurium, clindamycin, daptomycin, dexmedetomidine, docetaxel, doxorubicin liposome, drotrecogin alfa, etoposide phosphate, famotidine, fenoldopam, filgrastim, fluconazole, fludarabine, gallium nitrate, gemcitabine, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), labetalol, leucovorin, linezolid, melphalan, meperidine, morphine, paclitaxel, pantoprazole, pemetrexed, pentamidine, promethazine, propofol, remifentanil, sargramostim, tacrolimus, telavancin, teniposide, theophylline, thiotepa, vancomycin, warfarin, zidovudine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Foscarnet, heparin, lidocaine, metronidazole.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for injection: Prior to reconstitution, store at room temperature &le;25&deg;C (&le;77&deg;F). Protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Premixed solution (manufacturer premixed): Store at -20&deg;C (-4&deg;F); once thawed, solutions are stable for 3 days at room temperature of 25&deg;C (77&deg;F) or for 21 days refrigerated at 5&deg;C (41&deg;F). Do not refreeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Stability of reconstituted solutions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     10-40 mg/mL: Reconstituted in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, NS, or SWI: Stable for 2 days at room temperature of 25&deg;C (77&deg;F) or for 10 days when refrigerated at 4&deg;C (39&deg;F). Stable for 26 weeks when frozen at -20&deg;C (-4&deg;F) when reconstituted with D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS. Once thawed (at room temperature), solutions are stable for 2 days at room temperature of 25&deg;C (77&deg;F) or for 10 days when refrigerated at 4&deg;C (39&deg;F); does not apply to manufacturer's premixed bags. Do not refreeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     100 mg/mL: Reconstituted in D",
"     <sub>",
"      5",
"     </sub>",
"     W, SWI, or NS: Stable for 2 days at room temperature of 25&deg;C (77&deg;F) or for 10 days when refrigerated at 4&deg;C (39&deg;F). Reconstituted in lidocaine 1% solution or bacteriostatic water: Stable for 24 hours at room temperature of 25&deg;C (77&deg;F) or for 10 days when refrigerated at 4&deg;C (39&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     250-350 mg/mL: Reconstituted in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, lidocaine 1% solution, bacteriostatic water, or SWI: Stable for 24 hours at room temperature of 25&deg;C (77&deg;F) or for 3 days when refrigerated at 4&deg;C (39&deg;F).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Incompatible with calcium-containing solutions (including LR,  Hartmann's solution, or parenteral nutrition); do not mix or administer ceftriaxone simultaneously with calcium-containing solutions via a Y-site.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of sepsis, meningitis, infections of the lower respiratory tract, acute bacterial otitis media, skin and skin structure, bone and joint, intra-abdominal and urinary tract due to susceptible organisms (FDA approved in children and adults); surgical prophylaxis (FDA approved in adults); documented or suspected gonococcal infection or chancroid (FDA approved for children and adults); documented or suspected infection due to susceptible organisms in home care patients and patients without I.V. line access; treatment of emergency room management of patients at high risk for bacteremia, periorbital or buccal cellulitis, salmonellosis or shigellosis, and pneumonia of unestablished etiology (&lt;5 years of age); treatment of resistant acute otitis media; in children with acute otitis media who are unable to take oral antibiotics.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     As a third generation cephalosporin, ceftriaxone has activity against gram-negative aerobic bacteria (ie,",
"     <i>",
"      H. influenzae",
"     </i>",
"     , Enterobacteriaceae,",
"     <i>",
"      Neisseria",
"     </i>",
"     ), and activity against gram-positive cocci (ie, methicillin-susceptible",
"     <i>",
"      staphylococcal sp.",
"     </i>",
"     and",
"     <i>",
"      streptococcus sp.",
"     </i>",
"     ). Inactive against",
"     <i>",
"      Pseudomonas aeruginosa",
"     </i>",
"     ,",
"     <i>",
"      C. trachomatis",
"     </i>",
"     ,",
"     <i>",
"      methicillin resistant staphylococcus sp.",
"     </i>",
"     and",
"     <i>",
"      Enterococcus sp.",
"     </i>",
"     ).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F148257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       CefTRIAXone may be confused with CeFAZolin, cefoTEtan, cefOXitin, cefTAZidime, Cetraxal&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Rocephin&reg; may be confused with Roferon&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F148254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, leukopenia, thrombocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Induration, pain, tenderness at injection site (I.V.); warmth, tightness, induration following I.M. injection; pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal pain, agranulocytosis, alkaline phosphatase increased, allergic dermatitis, allergic pneumonitis, anaphylaxis, anemia, basophilia, biliary lithiasis, bilirubin increased, bronchospasm, chills, colitis, creatinine increased, diaphoresis, dizziness, dysgeusia, dyspepsia, edema, epistaxis, erythema multiforme, exanthema, fever, flatulence, flushing, gallbladder sludge, gallstones, glossitis, glycosuria, headache, hematuria, hemolytic anemia,  jaundice, leukocytosis, Lyell&rsquo;s syndrome, lymphocytosis, lymphopenia, moniliasis, monocytosis, nausea, nephrolithiasis, neutropenia, oliguria, palpitation, pancreatitis, phlebitis, prolonged or decreased PT, pruritus, pseudomembranous colitis, renal and pulmonary ceftriaxone-calcium precipitations (neonates including some fatalities), seizure, serum sickness Stevens-Johnson syndrome, stomatitis, thrombocytopenia , toxic epidermal necrolysis, urinary casts, urticaria, vaginitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Angioedema, allergic reaction, aplastic anemia, asterixis, cholestasis, encephalopathy, hemorrhage, hepatic dysfunction, hyperactivity (reversible), hypertonia, interstitial nephritis, LDH increased, neuromuscular excitability, pancytopenia, paresthesia, renal dysfunction, superinfection, toxic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ceftriaxone sodium, any component, or cephalosporins; do not use in hyperbilirubinemic neonates, particularly those who are premature since ceftriaxone is reported to displace bilirubin from albumin binding sites increasing the risk for kernicterus; do not use in neonates if they require or may require calcium-containing I.V. solutions (including parenteral nutrition solution)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with gallbladder, biliary tract, liver, or pancreatic disease; or in patients with history of colitis or penicillin hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in superinfection with yeasts, enterococci,",
"     <i>",
"      B. fragilis",
"     </i>",
"     , or",
"     <i>",
"      P. aeruginosa",
"     </i>",
"     . Do not use in patients with immediate-type hypersensitivity reactions to penicillin. Fatal reactions involving calcium-ceftriaxone precipitates in the lungs and kidneys of neonates have been reported, even when calcium-containing solutions were administered through separate sites and/or at different times. Ceftriaxone is incompatible with calcium and should not be reconstituted, admixed, or infused simultaneously with any calcium-containing solution (eg, LR, Hartmann&rsquo;s solution, parenteral nutrition) via a Y-site in any patient. Ceftriaxone and calcium-containing solutions may be administered sequentially in non-neonatal patients if the line is flushed thoroughly between infusions with a compatible solution. Severe cases (including some fatalities) of immune-related hemolytic anemia have been reported in patients receiving cephalosporins, including ceftriaxone; if hemolytic anemia develops, ceftriaxone should be discontinued until the etiology is identified.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F148168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts (Intravenous): May enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate. Management: Use of ceftriaxone with calcium-containing solutions within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ringer's Injection (Lactated): May enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium in the Lactated Ringer's forming an insoluble precipitate. Management: Use of ceftriaxone with calcium-containing solutions (including LR) within 48 hours of one another is contraindicated in neonates (28 days of age or younger).  In older patients, flush lines with compatible fluid between administration.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F148171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5952824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal reproduction studies. Ceftriaxone crosses the placenta and distributes to amniotic fluid. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins. Pregnancy was found to influence the single dose pharmacokinetics of ceftriaxone when administered prior to delivery. The pharmacokinetics of ceftriaxone following multiple doses in the third trimester are similar to those of nonpregnant patients. Ceftriaxone is recommended for use in pregnant women for the treatment of gonococcal infections, Lyme disease, and may be used in certain situations prior to vaginal delivery in women at high risk for endocarditis (consult current guidelines).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet count, PT, renal and hepatic function tests periodically; number and type of stools/day for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis resulting in cell wall death",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 6-14 L; widely distributed throughout the body including gallbladder, lungs, bone, bile, CSF (diffuses into the CSF at higher concentrations when the meninges are inflamed)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 85% to 95%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-4 days: 16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-30 days: 9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients (age not specified): 4.3-4.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Normal renal and hepatic function: 5-9 hours; renal impairment (mild to severe): 12-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Unchanged in the urine (33% to 67%) by glomerular filtration and in feces via bile",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content of 1 g: 3.6 mEq",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media, \"Diagnosis and Management of Acute Otitis Media,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 113(5):1451-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/15121972/pubmed\" id=\"15121972\" target=\"_blank\">",
"        15121972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Compogiannis LS, Murray WE, et al, &ldquo;Pharmacokinetics and Safety of Intramuscular Injection of Concentrated Ceftriaxone in Children,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1992, 11(11):961-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/1464221/pubmed\" id=\"1464221\" target=\"_blank\">",
"        1464221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Sexually Transmitted Diseases Treatment Guidelines, 2010, Gonococcal Infections,&rdquo; 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Committee on Adolescence, American Academy of Pediatrics, &ldquo;Sexual Assault and the Adolescent,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 94(5):761-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/7936916/pubmed\" id=\"7936916\" target=\"_blank\">",
"        7936916",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dowell SF, Butler JC, Giebink GS, et al, &ldquo;Acute Otitis Media: Management and Surveillance in an Era of Pneumococcal Resistance - A Report From the Drug-Resistant",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      Therapeutic Working Group,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1999, 18(1):1-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/9951971 /pubmed\" id=\"9951971 \" target=\"_blank\">",
"        9951971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frenck RW Jr, Nakhla I, Sultan Y, et al, \"Azithromycin Versus Ceftriaxone for the Treatment of Uncomplicated Typhoid Fever in Children,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2000, 31(5):1134-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/11073741/pubmed\" id=\"11073741\" target=\"_blank\">",
"        11073741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frenkel LD, \"Once-Daily Administration of Ceftriaxone for the Treatment of Selected Serious Bacterial Infections in Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1988, 82(3 Pt 2):486-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/3405685/pubmed\" id=\"3405685\" target=\"_blank\">",
"        3405685",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Low YM, Leong JL, and Tan HK, \"Paediatric Acute Epiglottitis Re-visited,\"",
"      <i>",
"       Singapore Med J",
"      </i>",
"      , 2003, 44(10):539-41",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/15024460/pubmed\" id=\"15024460\" target=\"_blank\">",
"        15024460",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village IL: American Academy of Pediatrics, 2009. Available at file://aapredbook.aappublications.org/cgi/content/full/2009/1/0.3. Accessed on July 21, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Richards DM, Heel RC, Brogden RN, et al, &ldquo;Ceftriaxone: A Review of Its Antibacterial Activity, Pharmacological Properties and Therapeutic Use,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1984, 27(6):469-527.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/6329638/pubmed\" id=\"6329638\" target=\"_blank\">",
"        6329638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sawyer SM, Johnson PD, Hogg GG, et al, \"Successful Treatment of Epiglottitis With Two Doses of Ceftriaxone,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1994, 70(2):129-32",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/8129435/pubmed\" id=\"8129435\" target=\"_blank\">",
"        8129435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stephens I and Levine MM, \"Management of Typhoid Fever in Children,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2002, 21(2):157-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/19/312/abstract-text/11840084/pubmed\" id=\"11840084\" target=\"_blank\">",
"        11840084",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13136 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_312=[""].join("\n");
var outline_f0_19_312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148198\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148199\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046122\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442229\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046115\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148175\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148159\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046125\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148255\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046119\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046124\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148257\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148254\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046128\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046114\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046113\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298998\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148168\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148171\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5952824\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046121\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046112\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046127\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046129\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13136\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13136|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=related_link\">",
"      Ceftriaxone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/39/24180?source=related_link\">",
"      Ceftriaxone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_19_313="Foot amputations";
var content_f0_19_313=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78430%7ESURG%2F54456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78430%7ESURG%2F54456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Foot amputations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Transmetatarsal, Lisfranc and Chopart amputations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 483px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_313=[""].join("\n");
var outline_f0_19_313=null;
var title_f0_19_314="Initial management of discoid lupus and subacute cutaneous lupus";
var content_f0_19_314=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial management of discoid lupus and subacute cutaneous lupus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/19/314/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/19/314/contributors\">",
"     Jennie Clarke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/19/314/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/19/314/contributors\">",
"     Jeffrey Callen, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/19/314/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/19/314/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/19/314/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4537206\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) are variants of cutaneous lupus that may occur independently or as manifestations of systemic lupus erythematosus. DLE most commonly occurs on the head and is characterized by well-defined inflammatory plaques that evolve into atrophic, disfiguring scars (",
"    <a class=\"graphic graphic_picture graphicRef64844 graphicRef75833 \" href=\"UTD.htm?17/33/17945\">",
"     picture 1A-B",
"    </a>",
"    ). SCLE typically presents with erythematous, scaly papules or annular plaques on the neck, upper trunk, and arms (",
"    <a class=\"graphic graphic_picture graphicRef66580 graphicRef55903 \" href=\"UTD.htm?39/29/40407\">",
"     picture 2A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Concern over the appearance of skin lesions leads most patients with DLE or SCLE to desire treatment, and the majority will respond to photoprotection combined with topical antiinflammatory agents or systemic antimalarial drugs. In particular, early treatment of DLE is essential to minimize scarring.",
"   </p>",
"   <p>",
"    The initial approach to the treatment of patients with DLE or SCLE will be discussed here. The clinical manifestations of DLE and SCLE and the management of patients with refractory disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H4#H4\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Discoid lupus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H7#H7\">",
"     \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Subacute cutaneous lupus erythematosus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31498?source=see_link\">",
"     \"Management of refractory discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1495831\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most individuals with DLE or SCLE require pharmacologic therapy to treat active skin lesions, the elimination of exacerbating factors is an important component of long term management. Strict photoprotection should be recommended, and photosensitizing medications should be discontinued if feasible. The possibility of drug-induced disease also needs to be considered in patients who present with SCLE, and should prompt discontinuation of any potential offending agents. (See",
"    <a class=\"local\" href=\"#H5875549\">",
"     'Nonpharmacologic measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For most patients with DLE or SCLE, topical corticosteroids are an appropriate first-line therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef78893 \" href=\"UTD.htm?43/36/44621\">",
"     algorithm 1",
"    </a>",
"    ). Topical calcineurin inhibitors, which lack the atrophogenic effects of corticosteroids, have also been shown to be effective for the treatment of cutaneous lupus. However, topical calcineurin inhibitors are more expensive than many topical corticosteroids, and may have a slower onset of action. Intralesional corticosteroid injections can be used to treat patients with focal lesions that do not respond to topical treatment. (See",
"    <a class=\"local\" href=\"#H4537249\">",
"     'Local therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    When DLE and SCLE are refractory to local therapy or local treatment is impractical due to the presence of extensive disease, systemic antimalarial therapy is often effective.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    is the most common agent used in the treatment of cutaneous lupus. Other systemic agents may also be tried if antimalarial therapy fails. (See",
"    <a class=\"local\" href=\"#H4537279\">",
"     'Systemic therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31498?source=see_link\">",
"     \"Management of refractory discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5875549\">",
"    <span class=\"h1\">",
"     NONPHARMACOLOGIC MEASURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4537221\">",
"    <span class=\"h2\">",
"     Photoprotection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DLE or SCLE should engage in sun-protective measures on a daily basis, including the use of broad spectrum sunscreens and sun protective clothing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/1\">",
"     1",
"    </a>",
"    ]. Exposure to ultraviolet light, and in rare cases visible light, can be an exacerbating factor for cutaneous lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. In experimental settings, exposure to ultraviolet light has been shown to induce skin lesions in approximately 70 to 100 percent of patients with SCLE [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/9-12\">",
"     9-12",
"    </a>",
"    ] and approximately 64 percent of patients with DLE [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/13\">",
"     13",
"    </a>",
"    ]. The latency period between sun exposure and the development of photo-induced skin lesions can last from several days to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, some patients may fail to associate exacerbations of skin lesions with photosensitivity.",
"   </p>",
"   <p>",
"    Few studies have addressed the efficacy of sunscreen in preventing the development of skin lesions. The following data support sunscreen use in this population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a company-sponsored, randomized, intraindividual trial of 25 patients with cutaneous lupus erythematosus (17 with lupus erythematosus tumidus, five with DLE, and three with SCLE), experimental UVA or UVB irradiation failed to induce skin lesions in all sites treated with a sun protective factor (SPF) 60 sunscreen containing ethylhexyl methoxycinnamate, titanium dioxide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      , and methylene bis-benzotriazolyl tetramethylbutylphenol (Tinosorb M) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/15\">",
"       15",
"      </a>",
"      ]. In contrast, skin lesions consistent with cutaneous lupus erythematosus developed in untreated or vehicle-treated sites in 16 (64 percent) and 14 patients (56 percent), respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\", section on 'Photoprotection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An intraindividual study of 11 patients with DLE or SCLE compared the ability of three different broad spectrum sunscreens to protect against the development of skin lesions after exposure to UVA and UVB [",
"      <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/16\">",
"       16",
"      </a>",
"      ]. All three sunscreens had protective effects. The most protective sunscreen prevented the development of skin lesions in all patients and had an SPF of 60. This sunscreen contained octocrylene, avobenzone, ecamsule (Mexoryl SX), drometrizole trisiloxane (Mexoryl XL), and titanium dioxide.",
"     </li>",
"     <li>",
"      A retrospective study found that an SPF 30 broad spectrum sunscreen containing avobenzone, octocrylene, ethylhexyl triazone, drometrizole trisiloxane, and titanium dioxide was highly effective in preventing new lesions following irradiation with UVA and UVB in 49 out of 51 patients with cutaneous lupus (primarily DLE or lupus tumidus) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An eight-week open label study, in which subjects with DLE and SCLE were instructed to apply a broad-spectrum sunscreen with an SPF greater than 15 that contained avobenzone and padimate O, demonstrated that daily use of this sunscreen led to a decrease in disease severity [",
"      <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the lack of large scale comparative trials addressing the efficacy of different sunscreens in the management of cutaneous lupus, patients generally should be advised to use broad spectrum, water-resistant sunscreens with an SPF of at least 30. However, typical patient use of sunscreen often provides insufficient protection for the photosensitive patient. The importance of other sun protective behaviors including the use of sun protective clothing, broad-brimmed hats, and sun avoidance (particularly during peak midday hours) must be emphasized. Specific products to reduce environmental UV exposure, such as UV blocking films for car windows, are also available [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection\", section on 'Photoprotection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4537235\">",
"    <span class=\"h2\">",
"     Avoidance of exacerbating drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug-induced SCLE presents with cutaneous and serologic findings similar to idiopathic disease. Medications that are associated with drug-induced SCLE should be discontinued or avoided when possible in patients with SCLE. A list of drugs associated with the development of SCLE is provided (",
"    <a class=\"graphic graphic_table graphicRef62265 \" href=\"UTD.htm?18/27/18876\">",
"     table 1",
"    </a>",
"    ). Withdrawal of the culprit agent often leads to resolution of the skin disease. However, many patients have persistently detectable autoantibodies",
"    <span class=\"nowrap\">",
"     (SSA/Ro",
"    </span>",
"    antibodies or",
"    <span class=\"nowrap\">",
"     SSB/La",
"    </span>",
"    antibodies), and a minority have persistent skin disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, medications that are known to cause photosensitivity may exacerbate symptoms in patients with idiopathic DLE or SCLE and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H21#H21\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Photosensitivity due to exogenous agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4537242\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of smoking cessation on patients with cutaneous lupus has not been studied. However, smoking has been associated with the development of cutaneous lupus and may contribute to the development of more severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. In a case control study of 108 patients with cutaneous lupus (majority with DLE or SCLE), patients with cutaneous lupus were more likely to be smokers than matched controls (OR 2.77, 95% CI 1.63-4.76) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/25\">",
"     25",
"    </a>",
"    ]. Smoking preceded the onset of symptoms in 91 percent of the affected smokers. Additional studies are necessary to determine the effect of smoking cessation on disease activity.",
"   </p>",
"   <p>",
"    Smoking may reduce the likelihood of the response of cutaneous lupus to systemic antimalarial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The mechanism through which smoking diminishes the efficacy of these agents remains unknown, but may involve nicotine interference with uptake of drug into cell lysosomes or the acceleration of the metabolic clearance of these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/28\">",
"     28",
"    </a>",
"    ]. It is unclear whether the use of nicotine substitutes (eg, chewing gums, patches, or inhalers) may have a similar effect, so when possible, smoking cessation without the use of these aids is preferable. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5875776\">",
"    <span class=\"h2\">",
"     Vitamin D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D deficiency may have deleterious effects on multiple organ systems. In addition to diet as a source of vitamin D, vitamin D is synthesized in the skin after sun exposure. Thus, the possibility of vitamin D deficiency should be considered in patients with cutaneous lupus, particularly those who engage in strict sun protective measures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In a study of 52 patients with cutaneous lupus, 65 percent exhibited 25(OH)D levels of less than 75",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    a level that is often defined as vitamin D insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/29\">",
"     29",
"    </a>",
"    ]. Vitamin D levels were significantly lower in subjects who engaged in daily sunscreen use or sun avoidance compared with those who did not. Due to the potential adverse effects of vitamin D deficiency, we typically screen patients with cutaneous lupus annually for this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=see_link\">",
"     \"Vitamin D and extraskeletal health\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low levels of vitamin D may play a role in autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/32\">",
"     32",
"    </a>",
"    ], and it is unknown whether low levels of vitamin D increase the risk for cutaneous lupus or augment the severity of the disease. One small, uncontrolled study reported no change in disease activity with vitamin D supplementation in patients with cutaneous lupus and vitamin D deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/33\">",
"     33",
"    </a>",
"    ]. There are no high quality studies investigating the effect of vitamin D supplementation on the prevention or treatment of cutaneous lupus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=see_link&amp;anchor=H651669#H651669\">",
"     \"Vitamin D and extraskeletal health\", section on 'Immune system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4537249\">",
"    <span class=\"h1\">",
"     LOCAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local therapies, such as topical corticosteroids, topical calcineurin inhibitors, or intralesional corticosteroids, are used in the treatment of most patients with cutaneous lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/34\">",
"     34",
"    </a>",
"    ]. For patients with widespread disease, in whom topical therapy alone is impractical, local therapies may be used as an adjunct to systemic medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4537257\">",
"    <span class=\"h2\">",
"     Topical corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical corticosteroids are appropriate first-line therapies for patients with DLE or SCLE, and some patients with localized disease can be adequately managed with photoprotection and topical corticosteroids alone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. For patients with extensive disease, topical corticosteroids are useful as a bridge therapy while awaiting the onset of slower-acting systemic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150535\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;High quality studies on the efficacy of topical corticosteroids for DLE and SCLE are limited, and the use of topical corticosteroids for DLE as first-line agents is primarily based upon documentation of successful treatment from early case reports and studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. In a double-blind trial (n = 20) in which two lesions on each patient were treated with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/22/36192?source=see_link\">",
"     fluocinolone",
"    </a>",
"    acetonide 0.025% ointment (a medium potency topical corticosteroid) three times daily or a vehicle control, fluocinolone was superior to the vehicle for the treatment of DLE [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/36\">",
"     36",
"    </a>",
"    ]. The same authors reported efficacy of fluocinolone acetonide 0.025% ointment in a series of 28 patients. After 18 days, 14 patients showed complete or almost complete regression of skin lesions and only two patients failed to improve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150542\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest twice daily application of a super high potency or high potency topical corticosteroid (Group 1 or 2) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate as first-line therapy for acute flares of DLE (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The use of very low potency agents is discouraged by the results of a randomized trial (n=78) in which application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"     fluocinonide",
"    </a>",
"    0.05% cream was superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    1% cream for the treatment of DLE (27 versus 10 percent achieved complete clearance or excellent improvement after six weeks of therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/39\">",
"     39",
"    </a>",
"    ]. Although the use of high potency topical corticosteroids on the face is typically avoided, they are often used for the treatment of facial DLE because of the importance of disease control for the minimization of scarring.",
"   </p>",
"   <p>",
"    Although there are no high quality studies of the efficacy of topical corticosteroids for the treatment of SCLE, our experiences and the clinical experiences of others support the efficacy of this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/10\">",
"     10",
"    </a>",
"    ]. We suggest twice daily application of a super high to medium potency topical corticosteroid (class 1 to 4) as initial therapy for acute flares of SCLE (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Improvement in DLE and SCLE with topical corticosteroids is typically noted within days to two weeks of the initiation of therapy. Data on maintenance regimens once disease control is attained are lacking. For patients with minimal disease activity on the face, we typically use twice daily application of a low-potency topical steroid (group 6 or 7) such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    1% or 2.5% (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 2",
"    </a>",
"    ). Twice daily application of medium to high potency topical corticosteroids (group 2 to 4), such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide 0.1% cream or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/56/30596?source=see_link\">",
"     fluocinonide",
"    </a>",
"    0.05% cream, can be used for trunk, extremity, or scalp disease. In general, the lowest-potency agent that maintains disease control should be utilized. When all signs of disease activity (eg, scale or erythema) are absent, treatment can be discontinued. Scarring and dyspigmentation will be unaffected by continued treatment.",
"   </p>",
"   <p>",
"    If an acute flare of DLE or SCLE has not responded to a high potency topical corticosteroid after two to four weeks, a topical calcineurin inhibitor or intralesional corticosteroid therapy should be tried (",
"    <a class=\"graphic graphic_algorithm graphicRef78893 \" href=\"UTD.htm?43/36/44621\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150549\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous atrophy is a potential side effect of the long term use of topical corticosteroids, particularly higher potency agents. Patients should be advised to limit the application of topical steroids to the involved skin only and should be followed closely for the development of atrophy. Adverse effects related to systemic absorption may also occur with topical corticosteroid use, especially when treating large areas of involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4537265\">",
"    <span class=\"h2\">",
"     Topical calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The topical calcineurin inhibitors are alternative drugs for the treatment of DLE or SCLE [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. These topical antiinflammatory agents are available as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    1% cream and as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.03% or 0.1% ointment. Topical calcineurin inhibitors do not induce cutaneous atrophy, a favorable feature for the treatment of lesions in locations (eg, face) where topical corticosteroids are most likely to induce cutaneous side effects. However, the calcineurin inhibitors are more expensive than topical corticosteroids, and may be slower-acting. In general, improvement in symptoms can be expected within the first four weeks of treatment, and complete clearance of thin patches or plaques may occur within two months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150484\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of topical calcineurin inhibitors for cutaneous lupus has been evaluated in a few randomized trials with limited numbers of patients and variable results. A 12-week, vehicle-controlled trial of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    0.1% ointment in 30 patients with various forms of cutaneous lupus refractory to topical corticosteroid therapy found limited evidence for the efficacy of tacrolimus specifically for DLE and SCLE [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/45\">",
"     45",
"    </a>",
"    ]. In the trial, which included 14 patients with DLE and 4 patients with SCLE, improvement in lesion severity was noted in tacrolimus-treated patients, but the degree of improvement was not superior to the improvement detected in vehicle-treated patients.",
"   </p>",
"   <p>",
"    Although these findings raise doubt about the efficacy of topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    for DLE and SCLE, the number of patients with DLE and SCLE was small, the study included patients who were failing to respond sufficiently to systemic therapies, and the timing of the study from August to November in Germany and encouragement of patient sunscreen use may have contributed to lesion regression due to decreased sun exposure. In contrast, two small randomized trials comparing topical tacrolimus and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    to topical corticosteroids, which are generally accepted to be effective for cutaneous lupus, suggest benefit from calcineurin inhibitors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an eight-week trial in which 10 patients with DLE were treated with either twice daily application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      1% cream or twice daily application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"       betamethasone",
"      </a>",
"      17-valerate 0.1% cream (a medium potency topical corticosteroid), there was no significant difference in efficacy or adverse effects between the two agents [",
"      <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/46\">",
"       46",
"      </a>",
"      ]. The mean clinical severity scores in the trial decreased by 86 and 73 percent, respectively.",
"     </li>",
"     <li>",
"      Another trial investigating the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      0.1% ointment versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"       clobetasol",
"      </a>",
"      propionate 0.05% ointment (a superpotent topical corticosteroid) for various forms of cutaneous lupus reported similar efficacy, but found an increased risk for the development of telangiectasias in subjects treated with clobetasol propionate [",
"      <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/47\">",
"       47",
"      </a>",
"      ]. The efficacy data from this trial may be less applicable since only 5 out of 20 patients in the trial had DLE or SCLE.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Uncontrolled studies also suggest efficacy of topical calcineurin inhibitors in small numbers of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. In an open label phase II study in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    0.1% cream was applied twice daily for eight weeks in 10 patients with DLE, improvement occurred in all; the mean reduction in the clinical severity score was 52 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/48\">",
"     48",
"    </a>",
"    ]. Benefit was also seen in a report of 11 patients with cutaneous lupus (6 patients with DLE or SCLE) who were treated with pimecrolimus 1% cream applied in the morning and under a hydrocolloid dressing at night [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/49\">",
"     49",
"    </a>",
"    ]. Statistically significant regression of skin lesions occurred in all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150491\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal clinical setting for the use of topical calcineurin inhibitors for DLE and SCLE has not been determined. Although the absence of cutaneous atrophy as an adverse effect is beneficial, concerns have been raised over the ability of these agents to penetrate thick, hypertrophic lesions of DLE [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, the longer time required to achieve disease control compared with topical corticosteroids make these agents less favorable when rapid improvement is desired. Thus, some authors have suggested using high potency topical corticosteroids for the initial treatment of severe, acute flares of DLE and SCLE, followed by the use of a topical calcineurin inhibitor once the acute flare is under control [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/43\">",
"     43",
"    </a>",
"    ]. Simultaneous therapy with topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/16/10502?source=see_link\">",
"     clobetasol",
"    </a>",
"    propionate has also been used with success in cutaneous lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We typically use topical calcineurin inhibitors for patients who have failed treatment with topical corticosteroids or for long-term therapy for thin lesions in atrophy-prone areas such as the face. Additional studies are necessary to establish the most appropriate use of topical calcineurin inhibitors in cutaneous lupus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H150498\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are generally well-tolerated. The most common side effect is a transient burning or stinging sensation after application that typically resolves within the first one to two weeks of use. In 2006, the US Food and Drug Administration (FDA) placed a black box warning on topical calcineurin inhibitors due to a concern for their potential carcinogenesis based on animal studies. However, the risk of this adverse affect with typical use of the drug appears to be small. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H423083\">",
"    <span class=\"h2\">",
"     Intralesional corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with focal lesions that do not respond to topical corticosteroids or topical calcineurin inhibitors can be treated with intralesional corticosteroid injections (",
"    <a class=\"graphic graphic_algorithm graphicRef78893 \" href=\"UTD.htm?43/36/44621\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3230368\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although this modality has been utilized by multiple experts for DLE and SCLE [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/10,19,53-58\">",
"     10,19,53-58",
"    </a>",
"    ], there are no high quality studies of intralesional corticosteroids for these indications. In one series of patients with DLE, a clinical response characterized as very good or excellent was achieved by 26 out of 40 patients treated with 3 or 4",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3230182\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     Triamcinolone",
"    </a>",
"    acetonide in concentrations ranging from 3 to 5",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    is typically used for treatment. A small diameter needle (ideally 30-gauge) is used to inject approximately 0.1 mL of the medication into the target site. Multiple injections within a single lesion should be placed approximately 1 cm apart. For patients who cannot tolerate the pain associated with injection, a topical anesthetic can be applied prior to the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link\">",
"     \"Intralesional injection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Injections are repeated every three to four weeks until erythema and scale are no longer present. If no response has occurred after two to three injections, alternative treatment should be considered.",
"   </p>",
"   <p>",
"    Some patients, most often those with SCLE, have too many lesions to treat successfully with intralesional corticosteroids alone due to the large number of injections that would be required [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/19\">",
"     19",
"    </a>",
"    ]. In the author&rsquo;s clinical practice, most patients are treated with less than 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide per session.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1590749\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with topical corticosteroids, cutaneous atrophy and pigmentary changes can occur with intralesional administration of corticosteroids. Periocular injections should be approached with caution, as central retinal artery occlusion leading to visual impairment is a potential adverse event [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/59\">",
"     59",
"    </a>",
"    ]. Systemic absorption also occurs with intralesional administration. In addition to the practical limitations of numerous injections, the risk of systemic side effects limits the use of this modality to disease involving small amounts of skin surface area. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=see_link&amp;anchor=H7#H7\">",
"     \"Intralesional injection\", section on 'Side effects, complications, and pitfalls'",
"    </a>",
"    .). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=see_link&amp;anchor=H16#H16\">",
"     \"General principles of dermatologic therapy and topical corticosteroid use\", section on 'Side effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4537272\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic retinoids have been used in the treatment of refractory cutaneous lupus, but evidence to support the efficacy of topical retinoids for this indication is limited to case reports describing the use of tretinoin 0.05% cream and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    0.05% gel for hypertrophic lesions of DLE [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The basis for the use of topical retinoids in cutaneous lupus is the ability of these drugs to decrease inflammation and slow abnormal differentiation and hyperproliferation of keratinocytes. We do not routinely use topical retinoids in the management of cutaneous lupus.",
"   </p>",
"   <p>",
"    Topical retinoids are contraindicated in pregnancy;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/17/19732?source=see_link\">",
"     tazarotene",
"    </a>",
"    is pregnancy category X. The most common side effect of topical retinoids is cutaneous irritation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4537279\">",
"    <span class=\"h1\">",
"     SYSTEMIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail to respond to topical agents or in whom topical or intralesional therapy is impractical due to widespread disease are candidates for systemic therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef78893 \" href=\"UTD.htm?43/36/44621\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/34\">",
"     34",
"    </a>",
"    ]. Antimalarials are the first-line systemic therapy for the treatment of DLE and SCLE, as they are effective for many patients and are generally well-tolerated. If a patient fails to improve with these drugs or cannot tolerate antimalarial therapy, other systemic agents may be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31498?source=see_link\">",
"     \"Management of refractory discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493864\">",
"    <span class=\"h2\">",
"     Antimalarials",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    , and quinacrine are the antimalarial agents that are utilized in the treatment of DLE and SCLE. Hydroxychloroquine and chloroquine are 4-aminoquinoline antimalarial compounds that have very similar pharmacokinetics, action, and metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In contrast, quinacrine is an acridine compound. In some countries, including the United States, quinacrine can only be obtained through specialty compounding pharmacies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5875580\">",
"    <span class=\"h3\">",
"     Efficacy and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of DLE or SCLE with antimalarials is most often initiated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    because it is generally accepted to have the best side effect profile;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    has a greater risk for of retinal toxicity and gastrointestinal intolerance, and quinacrine is more likely to cause hematologic adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/64\">",
"     64",
"    </a>",
"    ]. We treat most patients with a starting dose of 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    followed by an increase to 200 mg twice daily after one to two weeks if the drug is well tolerated. Starting with the once daily dose may reduce gastrointestinal side effects. The dosage of hydroxychloroquine should not exceed 6.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of lean body weight per day. Because there is a delay in the onset of action of antimalarials, six to eight weeks should elapse before efficacy is assessed.",
"   </p>",
"   <p>",
"    Many patients with cutaneous lupus will respond to monotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/56,65,66\">",
"     56,65,66",
"    </a>",
"    ]. In a randomized trial comparing treatment of cutaneous lupus with hydroxychloroquine to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/1/39958?source=see_link\">",
"     acitretin",
"    </a>",
"    (n=58), 50 percent of patients with DLE or SCLE treated with 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of hydroxychloroquine achieved complete clearance or marked improvement after eight weeks of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/65\">",
"     65",
"    </a>",
"    ]. Treatment success was also evident in a series of 34 patients with DLE; 24 (70 percent) achieved a good to excellent response with hydroxychloroquine (200 to 400",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for at least six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/56\">",
"     56",
"    </a>",
"    ]. Once satisfactory improvement is attained with hydroxychloroquine, the dose can be decreased to 200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If monotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    is unsuccessful, quinacrine can be added at a dose of 100 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/67-70\">",
"     67-70",
"    </a>",
"    ]. Results from the following studies suggest that combination therapy is beneficial in some patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of patients with various forms of cutaneous lupus who failed to respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      alone (19 patients with DLE and 10 with SCLE), combination therapy led to an 84 percent response rate and a statistically significant improvement in disease activity among the subjects with DLE [",
"      <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/67\">",
"       67",
"      </a>",
"      ]. Among the patients with SCLE, 60 percent showed improvement on clinical examination. However, the decrease in disease activity was not statistically significant.",
"     </li>",
"     <li>",
"      A prospective cohort study composed of patients with various forms of cutaneous lupus found that combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      and quinacrine significantly reduced disease activity in patients who had previously failed hydroxychloroquine; 10 out of 15 patients (67 percent) improved with combination therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/66\">",
"       66",
"      </a>",
"      ]. Due to the small number of patients, subtype-specific response rates could not be reliably assessed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Six to eight weeks should be allowed to pass before assessing the efficacy of the combination regimen. If treatment remains unsuccessful,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    may be substituted for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , because there is a small subset of patients who respond preferentially to this drug [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/19,66\">",
"     19,66",
"    </a>",
"    ]. The chloroquine dose should not exceed 3.5",
"    <span class=\"nowrap\">",
"     mg/kg/d.",
"    </span>",
"    Chloroquine and hydroxychloroquine should",
"    <strong>",
"     not",
"    </strong>",
"    be used together because of an unacceptably high risk of retinal toxicity.",
"   </p>",
"   <p>",
"    Topical steroids are useful in the early weeks of antimalarial therapy while awaiting the onset of action of the oral agents. Treatment failures are more likely in tobacco users as nicotine use decreases the effectiveness of antimalarials [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4537242\">",
"     'Smoking cessation'",
"    </a>",
"    above.) Many patients with purely cutaneous disease can discontinue their antimalarials during winter months when photoexacerbation is less of a problem.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5875587\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects of antimalarial therapy include gastrointestinal distress, ocular toxicity (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    ), and neuromuscular or hematologic abnormalities. Patients receiving hydroxychloroquine or chloroquine therapy should receive a baseline ophthalmologic exam and periodic ophthalmologic exams thereafter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H7#H7\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Adverse effects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=see_link&amp;anchor=H16#H16\">",
"     \"Antimalarial drugs in the treatment of rheumatic disease\", section on 'Monitoring for toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cutaneous alterations may also occur with antimalarial therapy, including blue-gray pigmentation on the shins, face, or palate, as well as bleaching of lightly pigmented hair. In addition, diffuse yellow discoloration of the skin, sclera, and body secretions is a frequent side effect of quinacrine therapy. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5872262\">",
"    <span class=\"h1\">",
"     REFRACTORY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients fails to respond to topical, intralesional, or systemic antimalarial therapy. Patients who do not attain sufficient improvement with the therapies above may benefit from other treatments. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31498?source=see_link\">",
"     \"Management of refractory discoid lupus and subacute cutaneous lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a prospective study of 300 patients with cutaneous lupus erythematosus, serum levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    correlated with treatment efficacy, suggesting that laboratory testing may be of value for distinguishing true resistance to hydroxychloroquine from factors such as poor patient compliance and inadequate drug dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?0/19/314/abstract/71\">",
"     71",
"    </a>",
"    ]. Further studies are necessary to determine the role of quantitative drug levels in the identification of antimalarial-resistant DLE and SCLE. The availability of the test is limited. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/5/16466?source=see_link\">",
"       \"Patient information: Discoid lupus (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4537286\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Discoid lupus erythematosus (DLE) and subacute lupus erythematosus (SCLE) may occur independently or in association with systemic lupus erythematosus. Concern over the appearance of skin lesions drives many patients to seek therapy. Treatment of discoid lupus early in the course of the disease is essential to minimize the development of disfiguring scarring. (See",
"      <a class=\"local\" href=\"#H4537206\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sun protective measures are an important component of the management of DLE and SCLE. Patients should use broad spectrum sunscreen with an SPF&ge;30 on a daily basis. Other sun protective measures, such as hats, protective clothing, and sun avoidance are an integral part of the treatment regimen. (See",
"      <a class=\"local\" href=\"#H4537221\">",
"       'Photoprotection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain medications can incite or exacerbate cutaneous lupus (",
"      <a class=\"graphic graphic_table graphicRef62265 \" href=\"UTD.htm?18/27/18876\">",
"       table 1",
"      </a>",
"      ). In patients with SCLE, medications that can induce the disorder should be identified and discontinued. Medications that increase photosensitivity also should be avoided or discontinued in patients with cutaneous lupus. (See",
"      <a class=\"local\" href=\"#H4537235\">",
"       'Avoidance of exacerbating drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with DLE or SCLE, we suggest the use of topical agents as first-line therapy (",
"      <a class=\"graphic graphic_algorithm graphicRef78893 \" href=\"UTD.htm?43/36/44621\">",
"       algorithm 1",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest treatment with topical corticosteroids over topical calcineurin inhibitors as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The relatively rapid onset of topical corticosteroids is beneficial.",
"     </li>",
"     <li>",
"      If topical corticosteroid therapy is not effective, we suggest treatment with a topical calcineurin inhibitor such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      0.1% ointment or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"       pimecrolimus",
"      </a>",
"      1% cream. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Topical calcineurin inhibitors also may be useful for long term therapy for lesions in areas of the skin where the risk of corticosteroid-induced atrophy is a concern. (See",
"      <a class=\"local\" href=\"#H4537257\">",
"       'Topical corticosteroids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4537265\">",
"       'Topical calcineurin inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with focal lesions of DLE or SCLE that fail to respond to topical therapy, we suggest treatment with intralesional corticosteroid injections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H423083\">",
"       'Intralesional corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who fail local therapy or who have extensive disease that makes topical or intralesional therapy impractical may benefit from systemic medications. We suggest treating these patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If therapy with hydroxychloroquine is unsuccessful, we suggest adding quinacrine 100",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Switching from hydroxychloroquine to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"       chloroquine",
"      </a>",
"      is an additional therapeutic option. (See",
"      <a class=\"local\" href=\"#H1493864\">",
"       'Antimalarials'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/1\">",
"      Kuhn A, Ruland V, Bonsmann G. Photosensitivity, phototesting, and photoprotection in cutaneous lupus erythematosus. Lupus 2010; 19:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/2\">",
"      EPSTEIN JH, TUFFANELLI D, DUBOIS EL. LIGHT SENSITIVITY AND LUPUS ERYTHEMATOSUS. Arch Dermatol 1965; 91:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/3\">",
"      Freeman RG, Knox JM, Owens DW. Cutaneous lesions of lupus erythematosus induced by monochromatic light. Arch Dermatol 1969; 100:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/4\">",
"      Cripps DJ, Rankin J. Action spectra of lupus erythematosus and experimental immunofluorescence. Arch Dermatol 1973; 107:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/5\">",
"      H&ouml;lzle E, Plewig G, Lehmann P. Photodermatoses--diagnostic procedures and their interpretation. Photodermatol 1987; 4:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/6\">",
"      Wolska H, Baszczyk M, Jaboska S. Phototests in patients with various forms of lupus erythematosus. Int J Dermatol 1989; 28:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/7\">",
"      van Weelden H, Velthuis PJ, Baart de la Faille H. Light-induced skin lesions in lupus erythematosus: photobiological studies. Arch Dermatol Res 1989; 281:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/8\">",
"      Lehmann P, H&ouml;lzle E, Kind P, et al. Experimental reproduction of skin lesions in lupus erythematosus by UVA and UVB radiation. J Am Acad Dermatol 1990; 22:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/9\">",
"      Hymes SR, Russell TJ, Jordon RE. The anti-Ro antibody system. Int J Dermatol 1986; 25:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/10\">",
"      Callen JP, Klein J. Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum 1988; 31:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/11\">",
"      Herrero C, Bielsa I, Font J, et al. Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases. J Am Acad Dermatol 1988; 19:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/12\">",
"      David KM, Thornton JC, Davis B, et al. Morbidity and mortality in patients with subacute cutaneous lupus erythematosus (SCLE) (abstract). J Invest Dermatol 1984; 82:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/13\">",
"      Callen JP. Discoid lupus erythematosus--variants and clinical associations. Clin Dermatol 1985; 3:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/14\">",
"      Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 2001; 45:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/15\">",
"      Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. J Am Acad Dermatol 2011; 64:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/16\">",
"      Stege H, Budde MA, Grether-Beck S, Krutmann J. Evaluation of the capacity of sunscreens to photoprotect lupus erythematosus patients by employing the photoprovocation test. Photodermatol Photoimmunol Photomed 2000; 16:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/17\">",
"      Herzinger T, Plewig G, R&ouml;cken M. Use of sunscreens to protect against ultraviolet-induced lupus erythematosus. Arthritis Rheum 2004; 50:3045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/18\">",
"      Callen JP, Roth DE, McGrath C, Dromgoole SH. Safety and efficacy of a broad-spectrum sunscreen in patients with discoid or subacute cutaneous lupus erythematosus. Cutis 1991; 47:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/19\">",
"      Rothfield N, Sontheimer RD, Bernstein M. Lupus erythematosus: systemic and cutaneous manifestations. Clin Dermatol 2006; 24:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/20\">",
"      Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res 2009; 301:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/21\">",
"      Boeckler P, Milea M, Meyer A, et al. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency. Br J Dermatol 2005; 152:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/22\">",
"      Miot HA, Bartoli Miot LD, Haddad GR. Association between discoid lupus erythematosus and cigarette smoking. Dermatology 2005; 211:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/23\">",
"      Gallego H, Crutchfield CE 3rd, Lewis EJ, Gallego HJ. Report of an association between discoid lupus erythematosus and smoking. Cutis 1999; 63:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/24\">",
"      Koskenmies S, J&auml;rvinen TM, Onkamo P, et al. Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations. Lupus 2008; 17:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/25\">",
"      Boeckler P, Cosnes A, Franc&egrave;s C, et al. Association of cigarette smoking but not alcohol consumption with cutaneous lupus erythematosus. Arch Dermatol 2009; 145:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/26\">",
"      Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/27\">",
"      Rahman P, Gladman DD, Urowitz MB. Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus. J Rheumatol 1998; 25:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/28\">",
"      Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002; 11:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/29\">",
"      Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed 2008; 24:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/30\">",
"      Heine G, Lahl A, M&uuml;ller C, Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. Br J Dermatol 2010; 163:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/31\">",
"      Cutillas-Marco E, Morales-Su&aacute;rez-Varela M, Marquina-Vila A, Grant W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus 2010; 19:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/32\">",
"      Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus erythematosus. Autoimmun Rev 2006; 5:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/33\">",
"      Renne J, Werfel T, Wittmann M. High frequency of vitamin D deficiency among patients with cutaneous lupus erythematosus [corrected]. Br J Dermatol 2008; 159:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/34\">",
"      Chang AY, Werth VP. Treatment of cutaneous lupus. Curr Rheumatol Rep 2011; 13:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/35\">",
"      DOEGLAS HM. CHRONIC DISCOID LUPUS ERYTHEMATOSUS TREATED WITH TRIAMCINOLONE AND PLASTIC OCCLUSION. Dermatologica 1964; 128:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/36\">",
"      BJORNBERG A, HELLGREN L. Treatment of chronic discoid lupus erythematosus with fluocinolone acetonide ointment. Br J Dermatol 1963; 75:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/37\">",
"      Bjornberg A, Hellgren L. Topical treatment of chronic discoid lupus erythematosus with betamethason-17-valerate and fluocinolone acetonie-a double blind study. Indian J Dermatol 1966; 12:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/38\">",
"      Mitchell, AD, Mitchell, DM. Fluocinolone acetonide in the treatment of chronic discoid lupus erythematosus. Lancet 1962; 280:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/39\">",
"      Roenigk HH Jr, Martin JS, Eichorn P, Gilliam JN. Discoid lupus erythematosus. Diagnostic features and evaluation of topical corticosteroid therapy. Cutis 1980; 25:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/40\">",
"      Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2009; :CD002954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/41\">",
"      B&ouml;hm M, Gaubitz M, Luger TA, et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology 2003; 207:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/42\">",
"      Kanekura T, Yoshii N, Terasaki K, et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003; 148:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/43\">",
"      S&aacute;rdy M, Ruzicka T, Kuhn A. Topical calcineurin inhibitors in cutaneous lupus erythematosus. Arch Dermatol Res 2009; 301:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/44\">",
"      Tzellos TG, Kouvelas D. Topical tacrolimus and pimecrolimus in the treatment of cutaneous lupus erythematosus: an evidence-based evaluation. Eur J Clin Pharmacol 2008; 64:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/45\">",
"      Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol 2011; 65:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/46\">",
"      Barikbin B, Givrad S, Yousefi M, Eskandari F. Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study. Clin Exp Dermatol 2009; 34:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/47\">",
"      Tzung TY, Liu YS, Chang HW. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol 2007; 156:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/48\">",
"      Tlacuilo-Parra A, Guevara-Guti&eacute;rrez E, Guti&eacute;rrez-Murillo F, et al. Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus. Rheumatology (Oxford) 2005; 44:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/49\">",
"      Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/50\">",
"      Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/51\">",
"      Walker SL, Kirby B, Chalmers RJ. The effect of topical tacrolimus on severe recalcitrant chronic discoid lupus erythematosus. Br J Dermatol 2002; 147:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/52\">",
"      Madan V, August PJ, Chalmers RJ. Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study. Clin Exp Dermatol 2010; 35:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/53\">",
"      Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/54\">",
"      Knott HM, Mart&iacute;nez JD. Innovative management of lupus erythematosus. Dermatol Clin 2010; 28:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/55\">",
"      Callen JP. Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/56\">",
"      Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol 1982; 118:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/57\">",
"      Callen JP. Intralesional triamcinolone is effective for discoid lupus erythematosus of the palms and soles. J Rheumatol 1985; 12:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/58\">",
"      Gunasekera V, Jayaram H, Kashani S, et al. Refractory discoid lupus erythematosis of the eyelid successfully treated with intra-lesional triamcinolone. Eye (Lond) 2008; 22:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/59\">",
"      Edwards AO. Central retinal artery occlusion following forehead injection with a corticosteroid suspension. Pediatr Dermatol 2008; 25:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/60\">",
"      Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Cutis 1991; 47:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/61\">",
"      Edwards KR, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 1999; 41:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/62\">",
"      Ritschel WA, Hammer GV, Thompson GA. Pharmacokinetics of antimalarials and proposals for dosage regimens. Int J Clin Pharmacol Biopharm 1978; 16:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/63\">",
"      McChesney EW RN. Comparative metabolic studies of chloroquine and hydroxychloroquine. Arthritis Rheum 1964; 7:328.",
"     </a>",
"    </li>",
"    <li>",
"     Callen, JP, Camisa, C. Antimalarial agents. In: Comprehensive dermatologic drug therapy, 2nd ed, Wolverton SE (Ed), Elsevier Inc., Philadelphia 2007. p.259.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/65\">",
"      Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/66\">",
"      Chang AY, Piette EW, Foering KP, et al. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. Arch Dermatol 2011; 147:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/67\">",
"      Cavazzana I, Sala R, Bazzani C, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus 2009; 18:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/68\">",
"      Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994; 189:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/69\">",
"      Lipsker D, Piette JC, Cacoub P, et al. Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology 1995; 190:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/70\">",
"      Toubi E, Rosner I, Rozenbaum M, et al. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/19/314/abstract/71\">",
"      Franc&egrave;s C, Cosnes A, Duhaut P, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012; 148:479.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13772 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-629A639819-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_314=[""].join("\n");
var outline_f0_19_314=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4537286\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4537206\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1495831\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5875549\">",
"      NONPHARMACOLOGIC MEASURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4537221\">",
"      Photoprotection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4537235\">",
"      Avoidance of exacerbating drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4537242\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5875776\">",
"      Vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4537249\">",
"      LOCAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4537257\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150535\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150542\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150549\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4537265\">",
"      Topical calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150484\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150491\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H150498\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H423083\">",
"      Intralesional corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3230368\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3230182\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1590749\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4537272\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4537279\">",
"      SYSTEMIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1493864\">",
"      Antimalarials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5875580\">",
"      - Efficacy and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5875587\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5872262\">",
"      REFRACTORY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4537286\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13772|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?43/36/44621\" title=\"algorithm 1\">",
"      Treatment of cutaneous lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13772|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/56/16261\" title=\"picture 1A\">",
"      Discoid lupus - right cheek",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/11/8372\" title=\"picture 1B\">",
"      Discoid lupus - left ear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/61/7122\" title=\"picture 2A\">",
"      Subacute cutaneous lupus - papular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/11/12467\" title=\"picture 2B\">",
"      Subacute cutaneous lupus - annular plaques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13772|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/27/18876\" title=\"table 1\">",
"      Drugs causing SCLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 2\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/6/27752?source=related_link\">",
"      General principles of dermatologic therapy and topical corticosteroid use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/45/40660?source=related_link\">",
"      Intralesional injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31498?source=related_link\">",
"      Management of refractory discoid lupus and subacute cutaneous lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27142?source=related_link\">",
"      Overview of cutaneous photosensitivity: Photobiology, patient evaluation, and photoprotection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/5/16466?source=related_link\">",
"      Patient information: Discoid lupus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/29/31193?source=related_link\">",
"      Vitamin D and extraskeletal health",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_19_315="Umbilical cord gases at term";
var content_f0_19_315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Range of mean umbilical artery blood pH and gas values in term newborns",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        pH",
"       </td>",
"       <td>",
"        7.27 to 7.28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PCO",
"        <sub>",
"         2",
"        </sub>",
"        (mmHg)",
"       </td>",
"       <td>",
"        49.2 to 50.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HCO",
"        <sub>",
"         3",
"        </sub>",
"        -(mEq/L)",
"       </td>",
"       <td>",
"        22.0 to 23.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Base excess (mEq/L)",
"       </td>",
"       <td>",
"        -2.7 to -3.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_315=[""].join("\n");
var outline_f0_19_315=null;
var title_f0_19_316="Immunosuppressive rx infections";
var content_f0_19_316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=17\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53524&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=17\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infections associated with specific immunosuppressive regimens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Antilymphocyte globulins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T-cell depleting antibodies - activation of latent (herpes) viruses, fever, cytokine release",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacteria, Pneumocystis pneumonia, activation of hepatitis C and hepatitis B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Azathioprine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutropenia, possible role in human papillomavirus infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mycophenolate mofetil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early bacterial infection B-cell depression, possible role in late-onset CMV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cyclosporine/tacrolimus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased viral replication, B-cell depression, gingival infection, intracellular pathogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rapamycin (sirolimus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excess infections in combination with current agents, idiosyncratic pulmonary syndrome, often with concomitant respiratory pathogens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Plasmapheresis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encapsulated bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Costimulatory blockade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unknown so far (possible role in post-transplant lymphoproliferative disorder [PTLD])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Rituximab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        B-cell depletion, bacterial and viral infections",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_316=[""].join("\n");
var outline_f0_19_316=null;
var title_f0_19_317="Increasing plasma cholesterol and coronary risk";
var content_f0_19_317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60146&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Association of increasing plasma cholesterol and coronary risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 238px; background-image: url(data:image/gif;base64,R0lGODlhbAHuAMQAAP///wAAAO7u7hEREYiIiLu7u6qqqszMzCIiIjMzM93d3URERJmZmXd3d1VVVf/v72ZmZv8QEP+fn//Pz/9gYP9AQP9/f/8wMP+/v/8gIP/f3/8AAP9QUP9wcP+vr/+PjyH5BAAAAAAALAAAAABsAe4AAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSRQsBlgEFk5qbKgsEnKChJZ6ipaCVlp+mq5IMAQcol7KstICYLgG1uncKCQoABAMCuLvFcwKoCJnExs2Duc7Rf9DS1XrU1tl12NrdcNze4Wvg4uVm5ObpYejq7Vzs7vFX8PL1UvT2+Uqz+v0oAsOQ4PPnTgGqBb+MDCSoDoGsBEcWMixXIAABgARuFZE4MZyBAAkVBDCgsGM/kQga/zRwmJAIR5PdMl5StRFmvwIql5W0KW8YwJ8Ba/J01wCkLEtBh7wc2qyoyKNJYVRk8GIpU2M+gUZ9oWDAAKrMrrZLsOyALxkCEBBAALaFVbG7BIwEKJJkjAUNALCtCteKhj0JjlrS6aLBAhF7YwnuS8XDhr95Ah+FIAPVJcpuGUuZEEECHwFkf95InFnzE86eRZFm8da0DtR/FKicHdE1E9h/HMraCqS17RoaInQAVLGSAwcQd/428uAChUAfBQy4KEz58iHNn0MHmSABhJHWrwPJPkguAZnVhYof77yQgV8EGrR0uT5IhQuGBuTdV/8HhQsPGNIABEDV1h8P/wVYiP9cUIV3oA0JHsLgbg4+OEOEiGjFWw/8WFiDBRFMII9vFkoQYj0kHmiiiCh6OMOKjSRFmFIuxgAjI6AlVNSGPqQoHgYbpIZjAF9VgoCBNbKAmyPBWEIgkkmmsCSOABWQwAIAQRmlCVMuUpRgAfDI4ZYodOklmGFWuOUDGWgHiYZZyvBdKnyRSQJ5oBww4wsJwOKKmCT4yBiemuj3UQCY0UBAcqXZSegkHx3gQACBzfeCK6/USWZzHIASXQLCgEcDA+mZAKadAHAAYJ4BTJqAXHbRoBFrdmJ4SiquWMpCAQgBU+oKgjJl6yY+nSfAeTIYZIkymtY4rCZOCQboDsHaREH/BgqCEm2D6nn4wYmlZFWgmuvduMp7S1Q7kbmr6Jeuh+yuMuC43dYnwQYs0jLhJdPqoG4/ZpqyL1LkuhbwKhpqudzBYv1bD8MNr8eZBbZ1+NujFV+HcTGgXcTfxe1Jw+AADuwphMPpbNyMAgSgkoDH9LnWXAXeMCAZkSaP6dqz0UAwgCUk+xxrECiLw7MzDL4cUJwnm3Z0NAjA8nFfT0fj7tRidRBBtt3MK1oMAkxKZFu0whVvNgOnCUMvsBTV7FBnoy1tDQUcGRbc4JaTcA0Q6JpC0dLEzRQBUit21FAPULCBB+3INtt+lQ3daEcPgEhBvunoxm8MvdD0NkHfVoB5/zrFtYqcDBXJQrYKgNciQQYVYFBPdNNJ128Ora+CQQYZCCnPR714J2rM+mBQQe/9mIfe7TjkDooGHERgAdf5BBSf373Zo4Hi03eklcLmVL4BBZBNNOfm9ZZTeQQclD9R6hSmH87rsfNU0UVfy6/N6xnIzpTS+SOeN4yHvKukjXk3cF4iJlCBCHygLwcsWDG2Jz3qGfB7SrlENhI3PguKRVkB6JUEWbE+8v1Gc5QCny5CNzrN3A8js6JRM+jnv+UATwR1GSEodldA8aBEJSzRoSYI6Lv1yIROQowE9CroIZw0IGfZW8X2NtA9D6ELa6AQnwlrdLUkKHAO62vflrzGNP8BaoKGZIpgsgYAxRN88Q38q+GW1AiDObXRVEM8XhHTiMEZxLBskGCgA1FVAhCK0I93LMEb0UDBKhJyBChklAz+qMjFJOIBGJCABY7XwUeW4IXHoiQuEhkoQmgAAxboQAM3UAEOWMADE/DgI28IgBwiEgaLrMIEPGABDlRgAxGoQAcsgAH3eTIFP1wJSORkMWDdAZOa5CTsLCABDMjymCs4okVUmIZTpnKVrXxlC7FJAyeSklpr2GUvfxnMYRaTnDy4Hg4b4DkZigGam8zABqZZzWvC8wZyOcwIFjAAblbBm6qMACtdCct/GuEjZHOF5IiGBXX6EpjCJKYxHfrQ4QH/4CMTjWIV9lkBalqTo1A4QKtIMKnC2ROli6hEAlQSGIHqD6YLuhmlXPpSnCqCASpZnRl96o5cEpURzTyqOoyqVKQ2NR5MfWoioirVQ1C1qoW4KlafsVVzaLWrtgCrOL4q1jQU4Gds/FxZJzEdX6l1rZBQ6QgyNTm4tsJuegmpG+26CQbgFQF6RZNgB0vYwhr2sIhNrGIXy9jGOvaxkI2sYrkgVwDIhad/Q6e/eBCszmoWd58F7Wa50NZgvNWPoW1eam3g2dGK1rWq5cJZcXbaSa6WtbeVVW5RC9vYvtYNZFUkFoJbSisQt7hvOK4IlLvceTj3ucmFbhWYS93h8vW6/9jNrna3y93ueve74IVDV3Qy27QCoLznxMF4ByqLTKC3CGEDGljee160prcG8R2bCCxzC/oO4XyqoK9//zuT/ba3vrT1gh1HUNqCAqDBRVjwfusJYSKwDQBue/AnTKthtw7hwhkmBQkqPIQ+AeBPHeYwiUvspzSJmMEbdvAXNFJZALyixnR1iU5eDAAcY1YIdesxNW485B8DIcgA4LGPj7AoIc/1AEtmcnKUXGQwaMSvkDQAlhGj1x7tuMBbzisS+nbiv2rZzEcgc5LBjGYiYMpPZg4zYI3wZgPTSc5dnscy8IxnhezJFQfosxEIJwI+t5kIhC4BoAVdBFIJwNBZRv+Co0mw6EN3gcbQuGxlL+tnNxZg0zkewgJiBWooZzrUQRh1LD59aiP3htUi0HSrvTgjTJTayjqp8IqVsoxewKc6uwZC50qg6xhb+GUk8LWvhhFsH/Dq18w2doplDOReBUMAyr72tL9wPmgI2L4RngUylrWMAQcBfpagyrcTDOSjMGDcAWAWgs0rBBDKe930rncyMgHve4M7vAAPuMAHTvCCG/zgCE+4whfO8IY7/OEQj7jEJ07xikN8UvU0AoNcPYKMOAAJGDeBK2xqgwTgVQQfoXayETAA7B1Ip70KuRI2zgKP82mbNZD5CKTzq3LifAQp/yiRSvARkrsoMCQpymH/dI4EmmdzpS4ITMZhwHRg/NwG37FU0INegsBwfD1IF/qRQn4zEx/AMoQj0qQGYIC1k+RQloBcx39GJAY14GcfL7MlsGT1j+d3m38/zm7OviySBAYCCICIX/c+jKpXIiEqJRmR2j55EYgN7yO2KamINHSuU/rqHgr7d/LC9IwcySGkrrsrhJERkqclAGRr/c4tYQDpYOIjR3IFRGxeiUw4pACTkrvULYsABAgg8gAoO+5PnMKqe2UEkX903WWvdAxDnflgUanxtz70Eqg07zXSKWZCzgDLFFQ3EPgE8rlfUAF8CYkiCExbaP4zA3yHMgxiWaueIgsCzAkvwzB8mCIL/2aBc/dnWZagAEwnF4yyfp03dPJnfeBHUCNQFJTBfibwfVESdixlERUxAAcQdLIhGRDggAUVdMaRfFcXgbFmCbBQfweYfx73FJZiGMuigp/gCieHgyIQgwnofDJmgkJXUBFYFHmnUpBjgUO4hN53fUfnUQCAcUGXEdR2f0IYdFL3ep4jey2YKfW3fLrXdyqYdw4QKzq4Zp9ge59gEKCBc2DYfKD3eCJwhUN3gJOSd0VROG94gt33eVP3clAYci5Td7LgAMf3gHx4gj9TfKDXJIToheCxeCE0DDYnAOeDEDezALBgAHR3fJbxccNXaLrBd1WXEapAh+03iJiReCUwJ06BwYeysB9eZ3FUwHMIxIMf8YcsUHS0WAUj1wIqVWBR2HMuoAAs53K9mIzKuIzM2IzO+IzQGI3SOI3UWI3WeI3YmI3auI3c2I3e+I1YEAIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between plasma cholesterol concentration and six-year coronary heart disease risk in 361,662 men (ages 35 to 57) screened during the MRFIT study. There is a continuous, positive, graded correlation between the plasma cholesterol concentration and coronary risk. To convert plasma cholesterol to mmol/L, divide by 38.5.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Stamler J, Wentworth D, Neaton JD. JAMA 1986; 256:2823.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_317=[""].join("\n");
var outline_f0_19_317=null;
var title_f0_19_318="Valvular regurgitation dexfen";
var content_f0_19_318=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Prevalence of aortic regurgitation is increased with dexfenfluramine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 269px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 223 patients treated with dexfenfluramine (Dexfen) there is an increase in the presence of 2+ aortic regurgitation (AR) (6.3 versus 1.6 percent for control, p&lt;0.02*) and any degree of AR (21.5 versus 11 percent, p = 0.005&bull;). Additionally, there is a significant increase in any FDA-grade regurgitation of either the aortic or mitral valve in the dexfenfluramine patients (7.6 versus 2 percent, p = 0.01&Delta;).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Shively, BK, Roldan, CA, Gill, EA, et al, Circulation 1999; 100:2161.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_318=[""].join("\n");
var outline_f0_19_318=null;
var title_f0_19_319="APC probe";
var content_f0_19_319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Argon plasma coagulator probe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The disposable probes are available in 1.5 mm, 2.3 mm (the most commonly used size), and 3.2 mm. The standard probes are 220 cm long.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_19_319=[""].join("\n");
var outline_f0_19_319=null;
